A highly selective MAT2A inhibitor (SYH2039), a new Class 1 chemical drug developed by CSPC PHARMA (01093.HK) +0.080 (+1.227%) Short selling $24.53M; Ratio 7.921% , has been approved by the US Food and Drug Administration (FDA) to conduct clinical trials in the US, according to CSPC PHARMA's announcement.
The product already obtained approval from the National Medical Products Administration of China (NMPA) to conduct clinical trials in China in March.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-04-26 16:25.)
